Jinqiao Qian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/518479/publications.pdf

Version: 2024-02-01

687363 752698 19 410 13 20 h-index citations g-index papers 21 21 21 604 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Research and Care, 2016, 4, e000227.	2.8	64
2	Uncovering novel landscape of cardiovascular diseases and therapeutic targets for cardioprotection via long noncoding RNA–miRNA–mRNA axes. Epigenomics, 2018, 10, 661-671.	2.1	56
3	Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-Î ³ -independent manner. Basic Research in Cardiology, 2011, 106, 431-446.	5.9	42
4	Involvement of miR-665 in protection effect of dexmedetomidine against Oxidative Stress Injury in myocardial cells via CB2 and CK1. Biomedicine and Pharmacotherapy, 2019, 115, 108894.	5.6	28
5	Dexmedetomidine exerts cardioprotective effect through miR-146a-3p targeting IRAK1 and TRAF6 via inhibition of the NF-κB pathway. Biomedicine and Pharmacotherapy, 2021, 133, 110993.	5.6	25
6	Dexmedetomidine preconditioning attenuates ischemia/reperfusion injury in isolated rat hearts with endothelial dysfunction. Biomedicine and Pharmacotherapy, 2019, 114, 108837.	5.6	24
7	Impact of HMGâ€CoA reductase inhibition on oxidantâ€induced injury in human retinal pigment epithelium cells. Journal of Cellular Biochemistry, 2011, 112, 2480-2489.	2.6	23
8	Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1806-H1817.	3.2	20
9	Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine. Cellular Physiology and Biochemistry, 2018, 50, 552-568.	1.6	18
10	Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signaling pathway axis. Biomedicine and Pharmacotherapy, 2020, 125, 110001.	5.6	18
11	Dexmedetomidine alleviates H2O2-induced oxidative stress and cell necroptosis through activating of α2-adrenoceptor in H9C2 cells. Molecular Biology Reports, 2020, 47, 3629-3639.	2.3	18
12	Oxytocin ameliorates ischemia/reperfusion-induced injury by inhibiting mast cell degranulation and inflammation in the rat heart. Biomedicine and Pharmacotherapy, 2020, 128, 110358.	5.6	15
13	The administration of dexmedetomidine changes microRNA expression profiling of rat hearts. Biomedicine and Pharmacotherapy, 2019, 120, 109463.	5.6	13
14	Dexmedetomidine preconditioning mitigates myocardial ischemia/reperfusion injury via inhibition of mast cell degranulation. Biomedicine and Pharmacotherapy, 2021, 141, 111853.	5.6	12
15	Aleglitazar, a Balanced Dual PPARÎ \pm and - \hat{l}^3 Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovascular Drugs and Therapy, 2016, 30, 129-141.	2.6	11
16	Aleglitazar, a dual peroxisome proliferator-activated receptor- \hat{l}_{\pm} and - \hat{l}_{\pm} agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diabetes and Vascular Disease Research, 2017, 14, 152-162.	2.0	8
17	Implication of regulatory networks of long noncoding RNA/circular RNA-miRNA-mRNA in diabetic cardiovascular diseases. Epigenomics, 2020, 12, 1929-1947.	2.1	8
18	Oxytocin mediated cardioprotection is independent of coronary endothelial function in rats. Peptides, 2020, 130, 170333.	2.4	3

#	Article	IF	CITATIONS
19	Risks of Impaired Organ Protection with Inhibiting Transient Receptor Potential Vanilloid 1. Anesthesiology, 2018, 129, 377-378.	2.5	1